EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma

Kentaro Yonekura iD, Ikko Muto, Motoi Takenaka iD, Jun Aoi, Taku Fujimura iD, Masahiro Amano, Takuro Kanekura, Takuya Miyagi iD, Kanami Saito iD, Eiji Kiyohara, Takatoshi Shimauchi iD, Ken Watanabe und 7 weitere

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17919 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Kentaro Yonekura und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Imamura General Hospital, Kagoshima, Japan. Hauptthemen laut MEDLINE: Bexarotene, Leukemia-Lymphoma, Adult T-Cell, Tetrahydronaphthalenes, Skin Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A multicenter, open‐label, historically controlled, 2‐arm phase II study was conducted to evaluate the safety, efficacy, and pharmacokinetics of bexarotene in Japanese patients with adult T‐cell lymphoma/leukemia (ATL). The study enrolled patients with indolent ATL and skin lesions and patients with aggressive ATL who had skin relapse after achieving remission following ≥ 1 regimen of systemic chemotherapy. Patients received oral bexarotene at an initial dose of 100 mg/m 2 (15 patients) or 300 mg/m 2 (17 patients) once daily for 24 weeks. The 100 mg/m 2 group included 14 patients with indolent ATL and 1 with aggressive ATL. The 300 mg/m 2 group included 14 patients with indolent ATL and 3 with aggressive ATL. Of 12 patients in the 100 mg/m 2 group, 6 patients achieved complete response (CR) or partial response (PR) as the best overall response (50.0%; 95% confidence interval (CI), 25.4%–74.6%). Of 17 patients in the 300 mg/m 2 group, 12 patients achieved CR or PR (70.6%; 95% CI, 46.9%–86.7%) as estimated with the modified Severity Weighted Assessment Tool (mSWAT). Drug‐related adverse events (AEs) occurred in 15 patients (100%) in the 100 mg/m 2 group and 16 of 17 patients (94.1%) in the 300 mg/m 2 group. The most common AEs were hypothyroidism (75.1%) and hypertriglyceridemia (53.1%). This is the first report to evaluate the safety and efficacy of bexarotene in ATL focused on skin lesions. In both groups, the response rate exceeded the threshold defined for the study. Bexarotene might be effective in improving skin lesions in ATL of any type with good tolerability. Trial Registration: This study was registered with the Japan Registry of Clinical Trials (jRCT2080224172)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BexaroteneLeukemia-Lymphoma, Adult T-CellTetrahydronaphthalenesSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeJapanAdministration, Oral

Stichwörter der Autor:innen

adult T‐cell leukemia/lymphomabexaroteneretionidskin lesionsystemic therapy

Substanzen

BexaroteneTetrahydronaphthalenes

Autor:innen und Institutionen

  • Department of Dermatology, Imamura General Hospital, Kagoshima, Japan.
  • Department of Dermatology, Kurume University, Kurume, Japan.
  • Department of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

ORCID-Profile: Kentaro Yonekura, Motoi Takenaka, Taku Fujimura, Takuya Miyagi, Kanami Saito, Takatoshi Shimauchi, Tomoko Miyake, Hisashi Uhara, Kazuyasu Fujii

Zitieren

APA

Yonekura, K., Muto, I., Takenaka, M., Aoi, J., Fujimura, T., Amano, M., Kanekura, T., Miyagi, T., Saito, K., Kiyohara, E., Shimauchi, T., Watanabe, K., Miyake, T., Ito, T., Uhara, H., Fujii, K., Sudo, A., Watanabe, T., & Iwatsuki, K. (2025). An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17919

Vancouver

Yonekura K, Muto I, Takenaka M, Aoi J, Fujimura T, Amano M, et al. An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17919

BibTeX
@article{Yonekura2025,
  author = {Yonekura, Kentaro and Muto, Ikko and Takenaka, Motoi and Aoi, Jun and Fujimura, Taku and Amano, Masahiro and Kanekura, Takuro and Miyagi, Takuya and Saito, Kanami and Kiyohara, Eiji and Shimauchi, Takatoshi and Watanabe, Ken and Miyake, Tomoko and Ito, Takamichi and Uhara, Hisashi and Fujii, Kazuyasu and Sudo, Akihito and Watanabe, Toshiki and Iwatsuki, Keiji},
  title = {An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17919}
}
Kostenlos starten →